The European Agency for the Evaluation of Medicinal Products
Veterinary Medicines and Inspections

London, 4 March 2004
EMEA/CVMP/021/04

PUBLIC STATEMENT ON
PULSAFLOX Oral Solution (difloxacin)

WITHDRAWAL OF THE MARKETING AUTHORISATION IN THE EUROPEAN UNION

On 16 November 2000 the European Commission granted a marketing authorisation valid throughout the European Union to Virbac S.A. for PULSAFLOX Oral Solution (difloxacin), indicated in chickens and turkeys for the treatment of chronic respiratory infections caused by sensitive strains of *Escherichia coli* and *Mycoplasma gallisepticum*. PULSAFLOX Oral Solution is also indicated in turkeys for the treatment of infections caused by *Pasteurella multocida*.

PULSAFLOX was not marketed anywhere in the European Union. On 15 December 2003 the Marketing Authorisation Holder notified the European Commission of its decision to voluntarily withdraw the Marketing Authorisation for PULSAFLOX oral solution for commercial reasons. An alternative is available in Europe (under a different invented name).

On 2 March 2004 the European Commission adopted the Decision withdrawing the Marketing Authorisation for the veterinary medicinal product "PULSAFLOX". Pursuant to this Decision the European Public Assessment Report for PULSAFLOX has been removed from the EMEA website.

Peter Jones
Head of Unit for Veterinary Medicines and Inspections

7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 8447
E-mail: mail@emea.eu.int http://www.eudra.eu.int